ASH 2022 | An update on the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph-like ALL
Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, provides an update on the Phase II GIMEMA LAL2317 trial (NCT03367299) assessing sequential chemotherapy and blinatumomab for Ph-like acute lymphoblastic leukemia (ALL). All patients receiving blinatumomab became measurable residual disease (MRD) negative, however relapse rates remained high. Dr Chiaretti highlights RNA sequencing data that indicated that patients who tended to relapse were more likely to be MRD positive before blinatumomab, suggesting that Ph-like ALL may comprise of several subtypes with different prognostic outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: Other: advisory board; Gilead: Other: advisory board; Abbvie: Other: advisory board; Incyte: Other: advisory board; Amgen: Other: advisory board.
